DOI: 10.5176/2315-4330_WNC15.63

Authors: Piotr Majkowski


This paper is the result of a Participatory Action Research project which sought to elucidate the experiences of nurses using the antipsychotic injectable medication Risperdal ® Consta ®. While nurses at Strathcona Mental Health Team felt that the injection device packaged with the medication failed frequently in a number of ways, the manufacturer believed that failures where uncommon. In the first phase of the study, an incident rate of 9.1{6e6090cdd558c53a8bc18225ef4499fead9160abd3419ad4f137e902b483c465} was identified. After manufacturing changes where introduced by the manufacturer, this rate seemed to decrease significantly. Actual numbers of incidents where further reduced by direction from the Vancouver Coastal Health Authority to stop using the medication where possible.

Keywords: antipsychotic, depot, product safety, syringe, intra-muscular, injection, SEMD

Price: $4.99

Loading Updating cart...